Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Lancet Haematol. 2019 Mar;6(3):e132–e143. doi: 10.1016/S2352-3026(18)30221-7

Figure 1.

CONSORT diagram.

Figure 1.

*Randomized trial patients who were replaced and removed from the trial due to: disease progression after randomization and prior to transplant (N=3), donor refusal to donate peripheral blood stem cells (N=2), and physician withdrew patient from the trial (N=1). Prospective cohort patients not eligible to be used as controls: AML not in complete remission at time of transplant (n=5), bone marrow graft recipient (n=1), patients performance score confirmed to be <70% (n=4) and recipients of myeloablative regimen (n=5).